Equities researchers at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a report issued on Sunday. The brokerage set a “hold” rating on the stock.
Separately, HC Wainwright reissued a “buy” rating and set a $19.00 target price on shares of Oncternal Therapeutics in a report on Friday, May 31st.
View Our Latest Research Report on ONCT
Oncternal Therapeutics Price Performance
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($2.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.88) by $0.05. Oncternal Therapeutics had a negative return on equity of 107.67% and a negative net margin of 3,160.73%. The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.18 million. During the same quarter last year, the firm posted ($4.00) EPS. As a group, equities analysts anticipate that Oncternal Therapeutics will post -11.63 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC purchased a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned 0.94% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 16.05% of the stock is currently owned by hedge funds and other institutional investors.
About Oncternal Therapeutics
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Further Reading
- Five stocks we like better than Oncternal Therapeutics
- Compound Interest and Why It Matters When Investing
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- How to Use the MarketBeat Stock Screener
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- What are earnings reports?
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.